{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0"},{"groupId":"OG001","value":"19.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"265"},{"groupId":"OG001","value":"265"}],"units":"Participants"}],"description":"Response rate of participants with stable disease. SD is the failure to achieve at least partial response (PR), but no evidence of progression for \\>8 weeks.","groups":[{"description":"Participants were randomized to sabatolimab plus Azacitidine","id":"OG000","title":"Sabatolimab (MBG453) + Azacitidine"},{"description":"Participants were randomized to placebo plus Azacitidine","id":"OG001","title":"Placebo + Azacitidine"}],"paramType":"NUMBER","populationDescription":"FAS comprised of all participants to whom study treatment had been assigned by randomization.","reportingStatus":"POSTED","timeFrame":"up to approx. 52 months","title":"Percentage of Participants With Stable Disease (SD) According to International Working Group for MDS (IWG-MDS) as Per Investigator Assessment","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}